Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Microdosing psychedelics: More questions than answers? An overview and suggestions for future research
Kim P. C. Kuypers, Livia Ng, David Erritzøe, et al.
Journal of Psychopharmacology (2019) Vol. 33, Iss. 9, pp. 1039-1057
Open Access | Times Cited: 171

Showing 26-50 of 171 citing articles:

Repeated low doses of LSD in healthy adults: A placebo‐controlled, dose–response study
Harriet de Wit, Hanna Molla, Anya K. Bershad, et al.
Addiction Biology (2022) Vol. 27, Iss. 2
Open Access | Times Cited: 53
Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of ‘magic mushroom’ consumption
Emma Morton, Kimberly Sakai, Amir Ashtari, et al.
Journal of Psychopharmacology (2022) Vol. 37, Iss. 1, pp. 49-60
Open Access | Times Cited: 45
Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT
Steven A. Barker
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1749-1763
Open Access | Times Cited: 38
The mechanistic divide in psychedelic neuroscience: An unbridgeable gap?
Bryan Barksdale, Manoj K. Doss, Gregory A. Fonzo, et al.
Neurotherapeutics (2024), pp. e00322-e00322
Open Access | Times Cited: 13
Neural complexity is increased after low doses of LSD, but not moderate to high doses of oral THC or methamphetamine
Conor H. Murray, Joel Frohlich, Connor J. Haggarty, et al.
Neuropsychopharmacology (2024)
Closed Access | Times Cited: 12
Psychedelic therapy in depression and substance use disorders
Nur Damla Korkmaz, Uğur Çıkrıkçılı, Merve Akan, et al.
European Journal of Neuroscience (2024) Vol. 60, Iss. 2, pp. 4063-4077
Open Access | Times Cited: 10
Illicit drug use among adolescents and young adults with impairments in the US: A cross-sectional analysis of the National Survey on Drug Use And Health
Justin A. Haegele, Samantha M. Ross, Jeanette M. Garcia
Preventive Medicine (2025) Vol. 191, pp. 108222-108222
Closed Access | Times Cited: 1
Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers
Nadia R. P. W. Hutten, Natasha L. Mason, Patrick C. Dolder, et al.
Frontiers in Psychiatry (2019) Vol. 10
Open Access | Times Cited: 60
The therapeutic potential of microdosing psychedelics in depression
Kim P. C. Kuypers
Therapeutic Advances in Psychopharmacology (2020) Vol. 10
Open Access | Times Cited: 60
Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities
Daniel Rosenbaum, Cory R. Weissman, Thomas Anderson, et al.
Journal of Psychopharmacology (2020) Vol. 34, Iss. 6, pp. 612-622
Closed Access | Times Cited: 56
Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults
Conor H. Murray, Ilaria Tare, Claire Perry, et al.
Psychopharmacology (2021) Vol. 239, Iss. 6, pp. 1735-1747
Open Access | Times Cited: 54
Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders
Toby Lea, Nicole Amada, Henrik Jungaberle, et al.
Psychopharmacology (2020) Vol. 237, Iss. 5, pp. 1521-1532
Closed Access | Times Cited: 53
From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders
Urszula Kozłowska, Charles D. Nichols, Kalina Wiatr, et al.
Journal of Neurochemistry (2021) Vol. 162, Iss. 1, pp. 89-108
Open Access | Times Cited: 52
Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers
Joseph M. Rootman, Pamela Kryskow, Kalin Harvey, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 52
Psychedelics as a Treatment for Alzheimer’s Disease Dementia
Simon Vann Jones, Allison O’Kelly
Frontiers in Synaptic Neuroscience (2020) Vol. 12
Open Access | Times Cited: 51
Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property
Guy A. Higgins, Nicole K. Carroll, Matthew A. Brown, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 48
Psychedelic perceptions: mental health service user attitudes to psilocybin therapy
Kate Corrigan, Maeve Haran, Conor McCandliss, et al.
Irish Journal of Medical Science (1971 -) (2021) Vol. 191, Iss. 3, pp. 1385-1397
Open Access | Times Cited: 46
Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls
Joseph M. Rootman, Maggie Kiraga, Pamela Kryskow, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 34
N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine
Edward James, Joachim Keppler, Thomas L Robertshaw, et al.
Human Psychopharmacology Clinical and Experimental (2022) Vol. 37, Iss. 3
Open Access | Times Cited: 30
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
Michael Tagen, Daniel Mantuani, Liron van Heerden, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 9, pp. 876-890
Closed Access | Times Cited: 20
The difference between ‘placebo group’ and ‘placebo control’: a case study in psychedelic microdosing
Balázs Szigeti, David Nutt, Robin Carhart‐Harris, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 18
Psilocybin’s effects on cognition and creativity: A scoping review
Justin N Bonnieux, Baeleigh VanderZwaag, Zahra Premji, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 7, pp. 635-648
Open Access | Times Cited: 17
Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study
Mauro Cavarra, Natasha L. Mason, Kim P. C. Kuypers, et al.
European Journal of Pain (2023) Vol. 28, Iss. 1, pp. 153-165
Open Access | Times Cited: 17
Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats
Kat F. Kiilerich, Joe Lorenz, Malthe B. Scharff, et al.
Molecular Psychiatry (2023) Vol. 28, Iss. 9, pp. 3829-3841
Open Access | Times Cited: 17
In the new era of psychedelic assisted therapy: A systematic review of study methodology in randomized controlled trials
Paul Soliman, Dallece E. Curley, Christy Capone, et al.
Psychopharmacology (2024) Vol. 241, Iss. 6, pp. 1101-1110
Closed Access | Times Cited: 6

Scroll to top